Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA080195-04
Application #
6489189
Study Section
Special Emphasis Panel (ZRG2-ET-1 (02))
Program Officer
Freeman, Colette S
Project Start
1999-01-01
Project End
2002-12-31
Budget Start
2002-01-01
Budget End
2002-12-31
Support Year
4
Fiscal Year
2002
Total Cost
$298,286
Indirect Cost

  Institution

Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212

  Publications

Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Hanker, Ariella B; Brewer, Monica Red; Sheehan, Jonathan H et al. (2017) An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov 7:575-585
Hanker, Ariella B; Estrada, Mónica Valeria; Bianchini, Giampaolo et al. (2017) Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Res 77:3280-3292
Hanker, Ariella B; Garrett, Joan T; Estrada, Mónica Valeria et al. (2017) HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 23:4323-4334
Whisenant, Jennifer G; McIntyre, J Oliver; Peterson, Todd E et al. (2015) Utility of [18?F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts. Mol Imaging Biol 17:119-28
Zabransky, Daniel J; Yankaskas, Christopher L; Cochran, Rory L et al. (2015) HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A 112:E6205-14
Young, Christian D; Arteaga, Carlos L; Cook, Rebecca S (2015) Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Breast Cancer Res 17:148
Arteaga, Carlos L; Engelman, Jeffrey A (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25:282-303
Whisenant, Jennifer G; Sorace, Anna G; McIntyre, J Oliver et al. (2014) Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts. Transl Oncol 7:768-79
Rexer, Brent N; Arteaga, Carlos L (2014) Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response. Breast Cancer Res 16:303

Showing the most recent 10 out of 109 publications